BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19040049)

  • 1. [Study on patients with benign prostate hyperplasia treated by the therapeutic regimen of watchful waiting during a twenty-four-month follow-up period].
    Zhang YG; Wang JY; Liu M; Xu J; Wu JY; Xin Y; Wan B; Wei D; Zhu SC; Zeng P
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):611-3. PubMed ID: 19040049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Data analysis of the objective observation parameters of benign prostatic hyperplasia patients accepting different treatment regimens].
    Zhang YG; Wang JY; Liu M; Wan B; Wei D; Deng SM; Xu J; Wu JY; Chu X; Zeng P
    Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1690-2. PubMed ID: 19024540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
    Xu J; Qian WQ; Song JD
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
    Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Watchful waiting in benign prostatic hyperplasia.
    Wiygul J; Babayan RK
    Curr Opin Urol; 2009 Jan; 19(1):3-6. PubMed ID: 19057209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transurethral ethanol injection therapy of benign prostatic hyperplasia: four-year follow-up.
    Sakr M; Eid A; Shoukry M; Fayed A
    Int J Urol; 2009 Feb; 16(2):196-201. PubMed ID: 19054163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy?
    Mochtar CA; Kiemeney LA; Laguna MP; Debruyne FM; de la Rosette JJ
    Prostate; 2006 Sep; 66(13):1407-12. PubMed ID: 16741919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of benign prostatic hyperplasia with hyperlipemia].
    Li PJ; Zhang XH; Guo LJ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):387-9. PubMed ID: 15854349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow-up.
    Hamann MF; Naumann CM; Seif C; van der Horst C; Jünemann KP; Braun PM
    Eur Urol; 2008 Oct; 54(4):902-7. PubMed ID: 18502565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of benign prostate hyperplasia.
    Wu SL; Li NC; Xiao YX; Jin J; Qiu SP; Ye ZQ; Kong CZ; Sun G; Na YQ
    Chin Med J (Engl); 2006 Dec; 119(24):2085-9. PubMed ID: 17199960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years.
    Djavan B; Fong YK; Harik M; Milani S; Reissigl A; Chaudry A; Anagnostou T; Bagheri F; Waldert M; Kreuzer S; Fajkovic H; Marberger M
    Urology; 2004 Dec; 64(6):1144-8. PubMed ID: 15596187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
    Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K
    Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
    Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
    Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the diagnostic criteria of bladder outlet obstruction in benign prostatic hyperplasia].
    Shuang W; Wang D; Zhang X; Liu C; Cao X; Wang J; Gao J; Ren Z; Lü Y
    Zhonghua Nan Ke Xue; 2004 Oct; 10(10):743-6. PubMed ID: 15562786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.